Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesTime to methotrexate treatment in patients with rheumatoid arthritis referred to hospital
Scandinavian Journal of Rheumatology , 10/20/09
de Thurah A et al. – The data from this study suggest that reduction in the time to start MTX treatment after referral to hospital could be improved, especially among patients with less severe symptoms. However, our results show that treatment practice in recent years has changed towards an earlier MTX treatment start.
Methods- Using prescription data, we conducted a large cohort study in County of Aarhus, Denmark, including all patients with first-time diagnosis of RA
- Kaplan-Meier used for estimates to compute the cumulative probability of MTX treatment start with follow-up starting on date of referral
- Defined early treatment start as MTX initiation within 90 days after referral
- 1516 RA patients
- Total of 703 (46%) started MTX treatment during study period
- Overall median time to treatment start 120 days
- Patients included in 2000-2006 had earlier MTX treatment start compared with patients included in 1996-1999 [adjusted incidence rate ratio (IRR) 1.83, 95% confidence interval (CI) 1.55-2
- Patients with CRP level > 300 nmol/L had earlier MTX treatment start compared with patients with moderate CRP level (adjusted IRR 1.36, 95% CI 1.16-1.73)
- Only 21% of patients started MTX within 90 days after referral and those were mainly patients included in later years and patients with high CRP
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09
Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
Osteoporosis International, 11/25/09
Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid
Osteoporosis International, 11/25/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production
Arthritis Research & Therapy, 11/25/09
Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis
Annals of Rheumatic Diseases, 11/24/09
Circulating microparticles remain associated with complement activation despite intensive anti-inflammatory therapy in early rheumatoid arthritis
Annals of Rheumatic Diseases, 11/23/09
Sponsor
Article Search
Sponsor